Moderna COVID-19 Vaccine Active Against Emerging Variants
In the US, a phase 1 study will evaluate mRNA-1273.351, an emerging variant booster candidate against the B.1.351 variant.
In the US, a phase 1 study will evaluate mRNA-1273.351, an emerging variant booster candidate against the B.1.351 variant.
A permanent FDA commissioner has not yet been nominated, but Woodcock is under consideration
If keeping to the authorized schedule is not feasible, the second dose may be scheduled for administration up to 42 days (6 weeks) after the first dose, according to ACIP.
Trivalent adjuvanted, trivalent high-dose inactivated influenza vaccines comparable for moderate-to-severe injection-site pain in adults 65 years and older
This week we have news of the neutralizing response of the Pfizer-BioNTech vaccine to the new COVID-19 variant; A trial investigated ravulizumab in adults with severe COVID is halted; A rapid blood test for concussions gets the all clear; A novel treatment for chronic kidney disease in patients with type 2 diabetes; And the drug manufacturer Fresenius Kabi announces a voluntary recall of one lot of an NSAID treatment.
Neutralizing antibodies detected in 90 percent or more of all participants on day 29 after the first vaccine dose.
The study was conducted by Pfizer and the University of Texas Medical Branch.
The V114 vaccine candidate consists of pneumococcal polysaccharides from 15 serotypes, including serotypes 22F and 33F, which are associated with invasive pneumococcal disease.
On the first MPR pod of 2021 we cover the latest COVID-19 vaccine news including admin. scheduling and production; A diagnostics test that may be giving false negative results; Bristol Myers Squibb withdraws an indication for Opdivo; And experts vote on the best diets for 2021.
In the United States, the CDC has said that COVID-19 vaccines ‘are not interchangeable’.